Astellas Pharma has acquired Universal Cells for $102.5m in a move to utilize the latter’s technology to produce pluripotent stem cells that have the potential to lower immunological rejection in various therapeutic areas.
CureVac, a biopharmaceutical company focused on developing mRNA-based drugs, has been awarded two new grants from the Bill & Melinda Gates Foundation.
Roivant Sciences and Poxel have signed a strategic development and license agreement for imeglimin, an investigational oral therapy which has been developed by Poxel for the potential treatment of type 2 diabetes, in the US, Europe and all other countries not covered by Poxel’s existing agreement in East and Southeast Asia.
Seattle Genetics and Pieris Pharmaceuticals partnered to develop multiple targeted bispecific immuno-oncology treatments for solid tumors and blood cancers.
Rexahn Pharmaceuticals has entered into a collaboration and license agreement with Zhejiang Haichang Biotechnology to develop RX-0201 (Archexin) for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
CVC Capital Partners has launched a new specialty pharmaceutical company in the UK following the completion of its $703m acquisition of a part of Israel-based Teva Pharmaceutical Industries’ global women’s health business.
Seattle Genetics has agreed to acquire Cascadian Therapeutics, a clinical-stage biopharmaceutical company engaged in the development of product candidates for the treatment of cancer, for around $614m.
Clinical-stage biotech company BridgeBio Pharma has licensed infigratinib (BGJ398), a selective inhibitor of the tyrosine kinase receptor FGFR and a late-stage oncology drug, from Novartis.
Innate Pharma has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca.
French drugmaker Sanofi has agreed to acquire Ablynx, a Belgian biopharma company focused in the discovery and development of Nanobodies, for about €3.9bn.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.